Jonathan Symonds, Director at Rubius Therapeutics, Inc. (RUBY), bought 25,000 shares at $23.00 ($575K) on 2018-07-20, disclosed to the SEC on 2018-07-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.